(Q36836817)

16 August 2017

1 reference

title

Are MAP kinases drug targets? Yes, but difficult ones (English)

1 reference

16 August 2017

Simona Margutti

1

1 reference

16 August 2017

Stefan A Laufer

series ordinal

2

1 reference

16 August 2017

publication date

1 August 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

2

1 reference

16 August 2017

issue

8

1 reference

16 August 2017

page(s)

1116-1140

1 reference

Components of a new human protein kinase signal transduction pathway

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for lipopolysaccharide stimulation of tumor necrosis factor alpha (TNF-alpha) translation: glucocorticoids inhibit TNF-alpha translation by blocking JNK/SAPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2FCMDC.200600271

21 January 2018

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Medicinal chemistry of target family-directed masterkeys

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.200600271

1 reference

7 January 2021

Too many targets, not enough target validation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.200600271

1 reference

7 January 2021

The Sequence of the Human Genome

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Initial sequencing and analysis of the human genome

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Can we learn to distinguish between "drug-like" and "nondrug-like" molecules?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Simple selection criteria for drug-like chemical matter

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Molecular properties that influence the oral bioavailability of drug candidates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Targeting signal transduction for disease therapy

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Bacterial signalling involving eukaryotic-type protein kinases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

The protein kinase family: conserved features and deduced phylogeny of the catalytic domains

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

The protein kinase complement of the human genome

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

The relation between the divergence of sequence and structure in proteins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

MAPK signalling: ERK5 versus ERK1/2.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

The ERK cascade: a prototype of MAPK signaling

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

A protein kinase involved in the regulation of inflammatory cytokine biosynthesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Extracellular signal-regulated kinases in T cells: characterization of human ERK1 and ERK2 cDNAs

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Characterization of the structure and function of a new mitogen-activated protein kinase (p38beta)

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinases, p38delta

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

The regulation of protein function by multisite phosphorylation--a 25 year update

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Heat-stable inhibitor protein derived peptide substrate analogs: phosphorylation by cAMP-dependent and cGMP-dependent protein kinases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.200600271

1 reference

7 January 2021

Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Ras is essential for nerve growth factor- and phorbol ester-induced tyrosine phosphorylation of MAP kinases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Activation of c-Raf-1 by Ras and Src through different mechanisms: activation in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Interdependent domains controlling the enzymatic activity of mitogen-activated protein kinase kinase 1.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Discovery of a novel Raf kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Kinase inhibition with BAY 43-9006 in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

The MAPK signaling cascade

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Signal transduction through MAP kinase cascades

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Targeting the Raf kinase cascade in cancer therapy--novel molecular targets and therapeutic strategies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

The stress-activated protein kinase subfamily of c-Jun kinases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

The p150-Spir protein provides a link between c-Jun N-terminal kinase function and actin reorganization

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

MAPKs: new JNK expands the group

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Glucocorticoids antagonize AP-1 by inhibiting the Activation/phosphorylation of JNK without affecting its subcellular distribution

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

All-trans-retinoic acid inhibits Jun N-terminal kinase-dependent signaling pathways

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Differentiation of CD4+ T cells to Th1 cells requires MAP kinase JNK2.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Defective T Cell Differentiation in the Absence of Jnk1

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

JNK2 is required for efficient T-cell activation and apoptosis but not for normal lymphocyte development.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Joint damage and inflammation in c-Jun N-terminal kinase 2 knockout mice with passive murine collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Targeting JNK for therapeutic benefit: from junk to gold?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Treatment of Parkinson's disease : what's on the horizon?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

p38 mitogen-activated protein kinase (MAPK) in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Activation of the novel stress-activated protein kinase SAPK4 by cytokines and cellular stresses is mediated by SKK3 (MKK6); comparison of its substrate specificity with that of other SAP kinases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

The primary structure of p38 gamma: a new member of p38 group of MAP kinases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Murine p38-delta mitogen-activated protein kinase, a developmentally regulated protein kinase that is activated by stress and proinflammatory cytokines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

The structure of mitogen-activated protein kinase p38 at 2.1-A resolution

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Crystal structure of p38 mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

The mixed lineage kinase SPRK phosphorylates and activates the stress-activated protein kinase activator, SEK-1.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

The p38 signal transduction pathway: activation and function

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Structural basis of inhibitor selectivity in MAP kinases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Molecular basis for p38 protein kinase inhibitor specificity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

From imidazoles to pyrimidines: new inhibitors of cytokine release

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Pyrroles and other heterocycles as inhibitors of p38 kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Kinetic mechanism for p38 MAP kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Small molecular anti-cytokine agents.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

The discovery of novel chemotypes of p38 kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Small molecule p38 inhibitors: novel structural features and advances from 2002-2005.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome P450 enzymes.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Substituted isoxazoles as potent inhibitors of p38 MAP kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Kinetics of small molecule inhibitor binding to p38 kinase.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidate

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Discovery of a new class of p38 kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Structural comparison of p38 inhibitor-protein complexes: a review of recent p38 inhibitors having unique binding interactions

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Pathway to the clinic: inhibition of P38 MAP kinase. A review of ten chemotypes selected for development

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Indole-based heterocyclic inhibitors of p38alpha MAP kinase: designing a conformationally restricted analogue

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Drugs, their targets and the nature and number of drug targets

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

STI571 as a targeted therapy for CML.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Issues and progress with protein kinase inhibitors for cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Strategies to overcome resistance to targeted protein kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Drug discovery: playing dirty

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Case histories, magic bullets and the state of drug discovery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.200600271

7 January 2021

Identifiers

DOI

10.1002/CMDC.200600271

1 reference

16 August 2017

1 reference